Hepatocellular Carcinoma in Non-Cirrhotic Liver

Hepatocellular carcinoma arising in a non-cirrhotic liver represents a distinct clinical entity characterised by tumour development in the absence of advanced fibrosis. Although historically uncommon, its incidence is increasing, driven in part by metabolic liver diseases, viral hepatitis in patients without cirrhosis, and cryptogenic mechanisms. These tumours often present at a later stage owing to lack of surveillance in non-cirrhotic populations, resulting in larger lesion size and higher symptom burden at diagnosis. Surgical resection remains the cornerstone of curative therapy, with outcomes generally favourable when detected early and resected radically. However, heterogeneity in aetiology, tumour biology and immune milieu poses challenges for screening strategies and adjuvant treatment. Current research focuses on refining risk stratification, developing novel biomarkers and tailoring multidisciplinary approaches to improve early detection and patient survival globally.

Research from Nature Portfolio

Recent studies have characterised a growing subset of cryptogenic non-cirrhotic hepatocellular carcinoma, noting a substantial rise in incidence over the past decade. Analysis of a large European referral cohort revealed that non-cirrhotic cases now account for over one-fifth of HCC diagnoses and that nearly 40 % lack an identifiable aetiology. These tumours display advanced stage at presentation, heightened systemic inflammation marked by elevated interleukin-6, and molecular profiles that parallel those seen in fatty-liver-associated HCC. Comparative immunoprofiling indicates overlapping biomarker signatures and genetic risk variants, such as PNPLA3, suggesting common pathways in cryptogenic and non-alcoholic fatty liver disease-related HCC. These insights underscore the need for targeted surveillance and biomarker development.

Hepatocellular Carcinoma in Non-Cirrhotic Liver publication trend

The graph below shows the total number of articles in hepatocellular carcinoma in non-cirrhotic liver across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatocellular carcinoma (HCC): Primary malignancy of liver parenchymal cells.

Non-cirrhotic liver: Liver tissue without advanced fibrosis or architectural distortion.

Non-alcoholic fatty liver disease (NAFLD): Spectrum of liver disorders characterised by excess fat deposition in hepatocytes unrelated to alcohol use.

Cryptogenic HCC: Hepatocellular carcinoma lacking a defined underlying liver disease.

Nomogram: Statistical prediction tool that provides individualised risk estimation based on multiple clinical parameters.

Alpha-fetoprotein (AFP): Serum glycoprotein used as a tumour marker for HCC surveillance and diagnosis.

Interleukin-6 (IL-6): Pro-inflammatory cytokine implicated in tumour growth and systemic inflammation.

References

1. Cryptogenic non-cirrhotic HCC: Clinical, prognostic and immunologic aspects of an emerging HCC etiology. Scientific Reports (2024).
2. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. Biomedicines (2023).
3. SEER-based risk stratification system for patients with primary non-cirrhotic liver cancer. Journal of Cancer Research and Clinical Oncology (2023).
4. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLOS ONE (2021).